GlassScriptPhysician profile
Mark Anthony East
NPI 1033137377
$9,959.81
in general payments reported to CMS, 2019-2025
40 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $1,206 · 2021: $1,201 · 2022: $1,028 · 2023: $1,558 · 2024: $1,849 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,955 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.85 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,588.47 | 2019-2025 | |
| Amgen INC. | $1,114.13 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,107.01 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.51 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $573.51 | 2019-2025 | Lifevest |
| Pfizer INC. | $459.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.72 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Amarin Pharma, INC. | $438.29 | 2019-2021 | |
| Cvrx, INC. | $408.97 | 2022-2025 | Barostim Neo System |
| Boston Scientific Corporation | $375.13 | 2019-2025 | Watchman Flx, Bodyguardian |
| Merck Sharp & Dohme LLC | $349.54 | 2021-2025 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $312.45 | 2019-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $242.85 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $225.50 | 2019-2022 | |
| Esperion Therapeutics, INC. | $206.38 | 2020-2025 | Nexletol |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $170.33 | 2020-2025 | Impella |
| Arbor Pharmaceuticals, INC. | $163.09 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.08 | 2025 | |
| Novo Nordisk INC | $126.99 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $111.49 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $84.17 | 2024 | Arcalyst |
| Biotronik INC. | $75.94 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $62.85 | 2019-2021 | |
| Vifor Pharma, INC. | $59.67 | 2019-2021 | |
| Cashflow Solutions, LLC | $57.90 | 2024-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Bridgebio Pharma, INC. | $55.09 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $53.17 | 2019-2020 | |
| Lundbeck LLC | $50.85 | 2019-2021 | |
| Braemar Manufacturing, LLC | $47.79 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $47.77 | 2023 | Arcalyst |
| Abbott Laboratories | $37.79 | 2019 | |
| Philips North America LLC | $28.40 | 2020 | |
| Baxter Healthcare | $27.58 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cleerly, INC. | $22.86 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Azurity Pharmaceuticals, INC. | $20.52 | 2023 | Horizant |
| G Medical Diagnostic Services, INC. | $15.78 | 2019 | |
| Irhythm Technologies, INC. | $15.27 | 2020 | |
| Medtronic, INC. | $14.35 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.27 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $10.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark East listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.